Cost‐effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation

Publisher： John Wiley & Sons Inc

E-ISSN： 1432-2277|28|9|1055-1065

ISSN： 0934-0874

Source： TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol.28, Iss.9, 2015-09, pp. : 1055-1065

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 544-563

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness of sofosbuvir in the treatment of patients with hepatitis C

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 4, 2015-04 ,pp. : 376-383

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation

By  

HEPATOLOGY, Vol. 61, Iss. 5, 2015-05 ,pp. : 1485-1494

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient with decompensated hepatitis C virus–related cirrhosis delisted for liver transplantation after successful sofosbuvir‐based treatment

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 3, 2015-03 ,pp. : 408-409

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness of strategies for testing current hepatitis C virus infection

By  

HEPATOLOGY, Vol. 62, Iss. 5, 2015-11 ,pp. : 1396-1404

John Wiley & Sons Inc

Access to resources Recommend Favorite